Mammalian Cell Culture Market Report 2026

The mammalian cell culture market size has grown rapidly in recent years. It will grow from $4.86 billion in 2025 to $5.4 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to expansion of monoclonal antibody production, growth in vaccine manufacturing capacity, increasing use of mammalian cells in drug discovery, rising availability of advanced culture equipment, growth of biopharmaceutical research.

The mammalian cell culture market size is expected to see rapid growth in the next few years. It will grow to $8.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing investments in cell and gene therapy, rising demand for biologics production, expansion of regenerative medicine research, growing focus on scalable cell culture technologies, increasing adoption of continuous bioprocessing. Major trends in the forecast period include increasing adoption of serum-free mammalian cell culture media, rising demand for large-scale biopharmaceutical production, growing use of automated cell culture systems, expansion of cell-based vaccine manufacturing, enhanced focus on process consistency and yield optimization.

The growing demand for personalized medicine is expected to drive the expansion of the mammalian cell culture market in the coming years. Personalized medicine tailors medical treatments based on individual genetic, environmental, and lifestyle factors to deliver more precise and effective care. The increasing adoption of personalized medicine is fueled by its ability to improve treatment outcomes by aligning therapies with a patient’s unique genetic and biological characteristics. Mammalian cell culture supports personalized medicine by offering a controlled setting to analyze patient-specific cells, enabling the development of customized therapies and the evaluation of drug responses for more targeted and effective treatments. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, a notable rise from six approvals in 2022. Consequently, the rising demand for personalized medicine is driving growth in the mammalian cell culture market.

Leading companies in the mammalian cell culture market are prioritizing innovations in cell culture media, including two-part production systems, to increase protein yields, enhance cell viability, and streamline scalable bioprocess workflows for therapeutic applications. A two-part production system is a cell culture method that uses separate media formulations, one optimized for cell growth and the other designed to boost protein expression, resulting in improved productivity. For instance, in July 2023, Lonza Group Ltd., a Switzerland-based contract development and manufacturing organization, introduced the TheraPRO CHO Media System. This chemically defined, animal-component-free media platform is specifically designed for GS-CHO mammalian cell lines and aims to enhance the production of therapeutic proteins and monoclonal antibodies by improving cell viability and increasing protein yields. Its scalable design supports bioprocess manufacturing across all stages, from cell line development to large-scale production. Through this launch, Lonza seeks to simplify workflows, improve product quality, and shorten time-to-market for biopharmaceutical manufacturers.

In December 2024, Merck KGaA, a Germany-based science and technology company, acquired HUB Organoids Holding B.V. for an undisclosed sum. Through this acquisition, Merck aims to strengthen its next-generation biology portfolio by integrating HUB’s organoid technology to accelerate drug discovery, expand three-dimensional cell culture capabilities, and deliver human-relevant models for disease research and toxicity testing. HUB Organoids Holding B.V., based in the Netherlands, specializes in mammalian cell culture-based organoid models that replicate human organ structure and function for research and therapeutic applications.

Major companies operating in the mammalian cell culture market are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, GE Healthcare, Becton Dickinson and Company, Lonza Group AG, Avantor Inc., Agilent Technologies Inc., Charles river laboratories, Sartorius AG, Samsung biologics, Wuxi biologics, Bio-Techne Corporation, Miltenyi Biotec, STEMCELL Technologies, Takara Bio Inc., Goodwin biotechnology, HiMedia Laboratories Private Limited, Promocell GmbH, Eppendorf AG, Cell Culture Company LLC, Cell X Technologies.

North America was the largest region in the mammalian cell culture market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mammalian cell culture market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mammalian cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the mammalian cell culture market by increasing costs of imported bioreactors, media components, reagents, filtration systems, and laboratory equipment used in research and manufacturing. Biopharmaceutical producers in North America and Europe are most affected due to reliance on imported high-value consumables, while Asia-Pacific faces higher capital costs for advanced production facilities. These tariffs are raising production expenses and affecting supply planning. However, they are also encouraging domestic production of culture media, regional equipment manufacturing, and localized bioprocess supply chain development.

The mammalian cell culture market research report is one of a series of new reports that provides mammalian cell culture market statistics, including mammalian cell culture industry global market size, regional shares, competitors with a mammalian cell culture market share, detailed mammalian cell culture market segments, market trends and opportunities, and any further data you may need to thrive in the mammalian cell culture industry. This mammalian cell culture market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mammalian cell culture is a technique used to grow animal cells under controlled laboratory conditions outside their natural environment. It involves maintaining cells in nutrient-rich media that supply essential growth factors, gases, and controlled conditions such as temperature and pH. This approach is widely applied in research, biotechnology, and medicine for studying cell biology, vaccine production, and drug testing. It enables scientists to closely replicate in vivo conditions and examine cellular behavior in a controlled setting.

The main products of mammalian cell culture include media, sera, reagents, and equipment. Media are nutrient-rich formulations designed to support the growth, proliferation, and maintenance of mammalian cells under regulated laboratory conditions. Key cell lines used include Chinese hamster ovary (CHO), Wistar Institute-38 (WI-38), rat glial tumor cell line (C6), human embryonic kidney 293 (HEK293), and Henrietta Lacks (HeLa). Major applications encompass biopharmaceutical production, vaccine manufacturing, toxicity testing, drug screening and development, and tissue engineering and regenerative medicine, with primary end-users comprising pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, research and academic institutes, and contract research organizations (CROs).

The mammalian cell culture market consists of sales of media, sera, reagents, equipment, bioreactors, culture plates, flasks, incubators, centrifuges, and microscopes. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.